Asia’s Probiotic Market Set for A Boost With Zuellig Pharma & Institut AllergoSan’s 10-Year Partnership

Zuellig Pharma, a major healthcare solutions provider in Asia, has unveiled a decade-long commercial partnership with Institut AllergoSan, an Austria-based R&D firm known for its natural substance products, including probiotics, plant extracts, and minerals. Through this collaboration, Zuellig Pharma will offer extensive commercialization support for OMNi-BiOTiC®, a top probiotic brand from Institut AllergoSan. This includes handling product registration, sales and marketing efforts, as well as warehousing and distribution to introduce the brand to major Asian markets.

John Graham, Group CEO, Zuellig Pharma, said in a statement “Our consumer healthcare segment will be one of the key growth drivers in our business over the coming years and this partnership represents a significant step forward in our commitment to delivering innovative and accessible healthcare solutions to patients in Asia. With a fast-growing probiotics market in Asia, the comprehensive and tailored solutions offered through our commercialisation division, ZP Therapeutics, will help our partners expand their footprint to meet greater consumer demand for gut health products in this region. Together with Institut AllergoSan, we will leverage our combined expertise to enhance the well-being of consumers and drive forward our mission of making healthcare more accessible.”

Anita Frauwallner, Founder & CEO of Institut AllergoSan, also added “We are dedicated to supporting consumers’ pursuit of a healthier, more vital self and offer medically relevant probiotic supplements that target specific health needs and deliver clinically backed results. OMNi-BiOTiC® is the top selling probiotic brand in all German-speaking markets in Europe such as Austria, Germany and Switzerland1 and we look forward to working closely with Zuellig Pharma to bring these innovative products to everybody in Asia who wants to promote an active, healthy life.”